Ophthotech Corp CEO David R. Guyer Sells 13,136 Shares (OPHT)
Ophthotech Corp (NASDAQ:OPHT) CEO David R. Guyer sold 13,136 shares of Ophthotech Corp stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $37.85, for a total transaction of $497,197.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Ophthotech Corp (NASDAQ:OPHT) traded up 0.71% on Monday, hitting $38.52. 213,511 shares of the company’s stock traded hands. Ophthotech Corp has a one year low of $22.61 and a one year high of $47.99. The stock has a 50-day moving average of $41.17 and a 200-day moving average of $36.33. The company’s market cap is $1.284 billion.
Ophthotech Corp (NASDAQ:OPHT) last announced its earnings results on Tuesday, May 13th. The company reported ($0.64) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.67) by $0.03. On average, analysts predict that Ophthotech Corp will post $-2.19 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Gabelli initiated coverage on shares of Ophthotech Corp in a research note on Friday, July 25th. They set a “buy” rating and a $40.00 price target on the stock. Separately, analysts at Goldman Sachs initiated coverage on shares of Ophthotech Corp in a research note on Friday, July 25th. They set a “neutral” rating and a $44.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Ophthotech Corp from $45.00 to $61.00 in a research note on Thursday, July 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Ophthotech Corp currently has a consensus rating of “Buy” and an average price target of $64.00.
Ophthotech Corporation is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.